ONCBeOne MedicinesSigning up patients
A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States
Advanced Unresectable Gastric Adenocarcinoma · Esophageal Squamous Cell Carcinoma · Advanced Gastroesophageal Adenocarcinoma
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.7
2 insiders sold shares within a month
Since Aug 3, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 2
- Patients
- 30 (planned)
- Started
- Apr 30, 2026
- Main results expected
- Dec 31, 2031
- Fully finished
- Dec 31, 2031
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
Measured over: Approximately 12 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.7, since 2026-08-03, fades (half-life)
Raw record changes
- none yet
Trial ID NCT07554521 · record last updated 2026-10-16 · checked 2026-11-09 15:47 UTC